GSA Capital Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

GSA Capital Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-49,160	Closed	-$1.83M	–	1914
2021 Q2	$1.83M	Buy	49,160 +39,869	+429%	+$1.22M	0.21%	67
2021 Q1	$238K	Sell	9,291 -10,397	-53%	-$266K	0.04%	792
2020 Q4	$434K	Sell	19,688 -4,700	-19%	-$104K	0.07%	511
2020 Q3	$439K	Buy	+24,388	New	+$505K	0.07%	474
2020 Q2	–	Sell	-10,225	Closed	-$188K	–	1286
2020 Q1	$188K	Sell	10,225 -45,964	-82%	-$893K	0.05%	780
2019 Q4	$1.24M	Buy	+56,189	New	+$1.13M	0.14%	120

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

GSA Capital Partners's DRNA Position: Q3 2021 in Review

GSA Capital Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 49,160 shares — an estimated $1.83M sold.

GSA Capital Partners first reported a position in DRNA in Q4 2019 and held it in 6 quarters. The position peaked at $1.83M in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

GSA Capital Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
GSA Capital Partners sold 49,160 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $1.83M.
GSA Capital Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
GSA Capital Partners's Dicerna Pharmaceuticals, Inc. position peaked at $1.83M in Q2 2021.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on GSA Capital Partners's 13F filing for Q3 2021, filed 12 Nov 2021.